Extraintestinal Manifestations and Intestinal Complications in Patients with Crohn's Disease: Associations with Some Clinico-Laboratory Findings, Immunological Markers and Therapy

Abstract Crohn's disease (CD) may have some severe complications that pose an increasing health burden and negatively impact the quality of life. There are two major types - intestinal and extraintestinal complications, in which immune and non-immune mechanisms take place. We aimed to search for some associations between specific extraintestinal manifestation and intestinal complications in CD patients with some clinicallaboratory findings, immunological markers, and the therapy administered. We examined retrospectively medical files of 26 patients with CD at mean age 42 ± 13 years, including the laboratory results. The immunological markers fecal calprotectin (FC) and fecal lactoferrin (FL) were assessed in frozen fecal samples of the chosen patients. Seventy-three percent of the investigated CD patients had some extraintestinal manifestation and/or intestinal complications, at least 13/26 had intestinal complications. All three patients with extraintestinal signs were positive for FC and 2/3 were positive for FL. We observed a higher serum level of CRP (24.49 mg/l vs. 3.13 mg/l, p = 0.010), slightly lowered serum level of hemoglobin (120 g/l vs. 145 g/l, p = 0.044) and about 2-fold lower iron level (7.23 μmol/l vs. 14.0 μmol/l, p = 0.019) in patients with intestinal complications compared to patients without complications, respectively. Four out of thirteen patients with intestinal complications were without immunosuppressive therapy at the time of our study, and nine out of thirteen - on immunosuppressive drugs. Routine laboratory and immunology testing could be beneficial for gastroenterologists in identifying patients at high risk for the development of complications and in the decision making for more aggressive therapy early after diagnosis.

[1]  L. A. Troncon,et al.  Extraintestinal manifestations of inflammatory bowel disease: Clinical aspects and pathogenesis. , 2018 .

[2]  K. Mahtani,et al.  Immunosuppression for management of Crohn's disease , 2016, The Lancet.

[3]  A. Bitton,et al.  Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial , 2015, The Lancet.

[4]  Hanan Khalil,et al.  Crohn’s disease: a clinical update , 2015, Therapeutic advances in gastroenterology.

[5]  H. Freeman Natural history and long-term clinical course of Crohn's disease. , 2014, World journal of gastroenterology.

[6]  M. Ciorba,et al.  Biomarkers in inflammatory bowel disease: current practices and recent advances. , 2012, Translational research : the journal of laboratory and clinical medicine.

[7]  J. Lewis The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. , 2011, Gastroenterology.

[8]  R. Burakoff,et al.  Extraintestinal Manifestations of Inflammatory Bowel Disease. , 2022, Rhode Island medical journal.

[9]  Esther Jacobowitz Israel,et al.  Shortcomings of the Inflammatory Bowel Disease Serology 7 Panel , 2010, Pediatrics.

[10]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[11]  Malfertheiner,et al.  World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. , 2010, Inflammatory bowel diseases.

[12]  T. Piche Impact de la chirurgie gynécologique sur le développement du syndrome de l’intestin irritable et des douleurs abdominales , 2008 .

[13]  E. Stange,et al.  Extraintestinal manifestations and complications in inflammatory bowel diseases. , 2006, World journal of gastroenterology.

[14]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[15]  A. Nakajima,et al.  Intestinal Antiinflammatory Effects of Thiazolidenedione Peroxisome Proliferator‐Activated Receptor‐&ggr; Ligands on T Helper Type 1 Chemokine Regulation Include Nontranscriptional Control Mechanisms , 2005, Inflammatory bowel diseases.

[16]  R. Fedorak Is it time to re-classify Crohn's disease? , 2004, Best practice & research. Clinical gastroenterology.

[17]  A. Peña,et al.  Treatment of extraintestinal manifestations in inflammatory bowel disease , 2003, Current treatment options in gastroenterology.

[18]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[19]  G. Hellers Crohn's disease in Stockholm county 1955-1974. A study of epidemiology, results of surgical treatment and long-term prognosis. , 1979, Acta chirurgica Scandinavica. Supplementum.

[20]  F. Bardachzi Vergleichende Untersuchungen bei Magenkrankheiten mit besonderer Berücksichtigung der Methoden zur Prüfung der motorischen Magenfunktion , 1911 .